Aripiprazole in the treatment of schizophrenia: A consensus report produced by schizophrenia experts in Italy

Clinical Drug Investigation

Volumn 27, Issue 1, 2007, Pages 1-13

  Cassano, Giovan B ^a   Fagiolini, Andrea ^b   Lattanzi, Lorenzo ^c   Monteleone, Palmiero ^d   Niolu, Cinzia ^e   Sacchetti, Emilio ^f   Siracusano, Alberto ^e   Vita, Antonio ^f  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c Clinica Psichiatrica Ospedale Sta Chiara   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIPHENHYDRAMINE; DOPAMINE 2 RECEPTOR; GABAPENTIN; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; PROPRANOLOL DERIVATIVE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

ACUTE DISEASE; AGITATION; AKATHISIA; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DEMOGRAPHY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUSTRY; DRUG INFORMATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; EXTRAPYRAMIDAL SYMPTOM; HEALTH PRACTITIONER; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; ITALY; LONG TERM CARE; MEDICAL EXPERT; MEDICAL PRACTICE; METABOLIC DISORDER; NAUSEA; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BINDING; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN;

EID: 33846087937     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727010-00001     Document Type: Conference Paper

References (56)

1. Diagnostic and statistical manual of mental disorders. 4th ed. (DSM-IV). Washington, DC: American Psychiatric Press, 1994
2. Flaum M, Schultz SK. The core symptoms of schizophrenia. Ann Med 1996; 28 (6): 525-31
3. Green AI, Canuso CM, Brenner MJ, et al. Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am 2003; 26 (1): 115-39
4. Sharma T, Antonova L. Cognitive function in schizophrenia: deficits, functional consequences, and future treatment. Psychiatr Clin North Am 2003; 26 (1): 25-40
5. Miller DD. Schizophrenia: its etiology and impact. Pharmacotherapy 1996; 16 (1 Pt 2): 2-5
6. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56 (3): 241-7
7. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004; 30 (2): 279-93
8. Rupp A, Keith SJ. The costs of schizophrenia: assessing the burden. Psychiatr Clin North Am 1993; 16 (2): 413-23
9. Meltzer HY. Outcome in schizophrenia: beyond symptom reduction. J Clin Psychiatry 1999; 60 Suppl. 3: 3-7
10. Moller HJ. Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs 2003; 17 (11): 793-823
11. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 2005; 28 (3): 191-208
12. Sharma T. Impact on cognition of the use of antipsychotics. Curr Med Res Opin 2002; 18 Suppl. 3: s13-7
13. Wirshing DA. Adverse effects of atypical antipsychotics. J Clin Psychiatry 2001; 62 Suppl. 21: 7-10
14. Wirshing WC. Movement disorders associated with neuroleptic treatment. J Clin Psychiatry 2001; 62 Suppl. 21: 15-8
15. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc 2005; 80 (8): 1050-7
16. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64 (20): 2291-314
17. Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry 2005; 66 Suppl. 6: 5-10
18. Tandon R, Halbreich U. The second-generation 'atypical' antipsychotics: similar improved efficacy but different neuroendocrine side effects. Psychoneuroendocrinology 2003; 28 Suppl. 1: 1-7
19. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353 (12): 1209-23
20. Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 1978; 135 (2): 165-73
21. Risch SC. Pathophysiology of schizophrenia and the role of newer antipsychotics. Pharmacotherapy 1996; 16 (1 Pt 2): 11-4
22. Yasuno F, Suhara T, Okubo Y, et al. Low dopamine D2 receptor binding in subregions of the thalamus in schizophrenia. Am J Psychiatry 2004; 161 (6): 1016-22
23. Grunder G, Kungel M, Ebrecht M, et al. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry 2006; 39 Suppl. 1: S21-5
24. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302 (1): 381-9
25. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry 2001; 62 (12): 923-4
26. Kane JM, Leucht S, Carpenter D, et al. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003; 64 Suppl. 12: 5-19
27. Travis MJ, Burns T, Dursun S, et al. Aripiprazole in schizophrenia: consensus guidelines. Int J Clin Pract 2005; 59 (4): 485-95
28. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004; 44 (2): 179-87
29. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63 (9): 763-71
30. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60 (7): 681-90
31. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003; 6 (4): 325-37
32. Kern RS, Green MF, Cornblatt BA, et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl) 2006; 187 (3): 312-20
33. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2006; (2): CD004578
34. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003; 64 (9): 1048-56
35. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61 (2-3): 123-36
36. US FDA Center for Drug Evaluation and Research. Medical review (s) Part 1-4: review and evaluation of clinical data NDA #21-436, 2002 Available from URL: http//www.fda.gov/cdev/foi/nda/2002/21-436 [Accessed 2006 Nov 30]
37. Carson Jr WH, Archibald D, Manos G, et al. Short-term efficacy of aripiprazole on depression and anxiety in schizophrenia. American Psychiatric Association 2003 Annual Meeting: New Research Abstracts 2003: abstract no. NR549
38. Dillenschneider A, Marcus R, Kostic D, et al. Effects of aripiprazole on the excitement/hostility symptoms of schizophrenia [abstract]. Int J Neuropsychopharmacol 2004; 7 Suppl. 1: S243
39. Marder S, Archibald D, Manos G, et al. Long-term effects of aripiprazole therapy on the negative symptoms of schizophrenia [abstract]. Int J Neuropsychopharmacol 2004; 7 Suppl. 1: S243
40. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004; 65 Suppl. 18: 47-56
41. National Institute for Clinical Excellence (NICE) Technology Appraisal Guidance. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. London: NICE, 2002
42. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. 2nd ed [online]. Available from URL: http://www.psych.olg [Accessed 2006 Aug 1]
43. Bristol-Myers Squibb Company and Otsuka America Pharmaceutical Inc. Abilify (aripiprazole) tablets prescribing informania: tion [online]. Available from URL: http://www.ability.com [Accessed 2006 Aug 1]
44. Tandon R, Marcus RN, Stock EG, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial with Aripiprazole (BETA). Schizophr Res 2006; 84 (1): 77-89
45. Haas GL, Garratt LS, Sweeney JA. Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness. J Psychiatr Res 1998; 32 (3-4): 151-9
46. Lieberman JA, Fenton WS. Delayed detection of psychosis: causes, consequences, and effect on public health. Am J Psychiatry 2000; 157 (11): 1727-30
47. McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry 1999; 46 (7): 899-907
48. Ward ME, Saklad SR, Ereshefsky L. Lorazepam for the treatment of psychotic agitation. Am J Psychiatry 1986; 143 (9): 1195-6
49. Bodkin JA. Emerging uses for high-potency benzodiazepines in psychotic disorders. J Clin Psychiatry 1990; 51 Suppl.: 41-6
50. Gillies D, Beck A, McCloud A, et al. Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis. Cochrane Database Syst Rev 2005; (4): CD003079
51. Citrome L. Schizophrenia and valproate. Psychopharmacol Bull 2003; 37 Suppl. 2: 74-88
52. Hosak L, Libiger J. Antiepileptic drugs in schizophrenia: a review. Eur Psychiatry 2002; 17 (7): 371-8
53. Ganguli R. Rationale and strategies for switching antipsychotics. Am J Health Syst Pharm 2002; 59 (22 Suppl. 8): S22-6
54. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003; 166 (4): 391-9
55. Correll CU. Real-life switching strategies with second-generation antipsychotics. J Clin Psychiatry 2006; 67 (1): 160-1
56. Peuskens J. Switching approach in the management of schizophrenia patients. Int Clin Psychopharmacol 2000; 15 Suppl. 4: S15-9